-
Je něco špatně v tomto záznamu ?
Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries
S. Jakubowski, P. Kawalec, P. Holko, I. Kowalska-Bobko, M. Kamusheva, G. Petrova, P. Draganić, L. Fuksa, A. Männik, F. Ispán, V. Briedis, I. Bianchi, MS. Paveliu, T. Tesar
Status neindexováno Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Free Medical Journals od 2010
PubMed Central od 2010
Europe PubMed Central od 2010
Open Access Digital Library od 2010-01-01
Open Access Digital Library od 2010-01-01
ROAD: Directory of Open Access Scholarly Resources od 2010
Odkazy
PubMed
38523639
DOI
10.3389/fphar.2024.1369178
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Objectives: The aim of this study was to characterize the reimbursement policy for orphan drugs (ODs) in Central and Eastern European (CEE) countries in relation to the availability and impact of clinical evidence, health technology assessment (HTA) procedure, selected economic indicators, and the drug type according to indications. Materials and methods: A list of authorized medicines with orphan designation and information about active substance, Anatomical Therapeutic Chemical (ATC) classification, and therapeutic area was extracted from the web-based register of the European Medicines Agency (EMA). A country-based questionnaire survey was performed between September 2021 and January 2022 in a group of selected experts from nine CEE countries (an invitation was sent to 11 countries). A descriptive and statistical analysis was conducted to determine statistical significance, correlations, between the drug or country characteristic and the positive recommendation or reimbursement of ODs.Results: The proportion of reimbursed orphan drugs differed between countries, ranging from 17.7% in Estonia to 49.6% in Hungary (p < 0.001). The odds that ODs were reimbursed were reduced in countries with a "strong" level of impact of drug safety and efficacy on reimbursement decisions (p=0.018), the presence of other additional specific clinical aspects (e.g., genomic data) considered in the reimbursement decision (p < 0.001) and mandatory (without exception) safety assessments (p=0.004). The probability that ODs were reimbursed was increased in countries with a "moderate" level of impact of drug safety and efficacy on reimbursement decisions (p=0.018), when reimbursement decisions are dependent on the EMA registration status and orphan drug designation (p < 0.001), the presence of the "positive HTA recommendation guarantees reimbursement" policy (p < 0.001), higher GDP per inhabitant (p=0.003), and higher healthcare expenditure (p < 0.001). Conclusion: We found that there are differences among CEE countries in the reimbursement of orphan drugs, and we identified aspects that may influence these differences. Safety, efficacy, and specific clinical aspect issues significantly influenced reimbursement decisions. Antineoplastic and immunomodulating agents drugs were the largest group of ODs and increased the chance of getting a positive recommendation. The higher GDP per inhabitant and healthcare expenditures per inhabitant were positively linked to the chance that an OD receives reimbursement.
Agency for Medicinal Products and Medical Devices of Croatia Zagreb Croatia
Department of Biotechnology University of Rijeka Rijeka Croatia
Department of Clinical Pharmacy of Lithuanian University of Health Sciences Kaunas Lithuania
Department of Reimbursement National Institute of Health Insurance Fund Management Budapest Hungary
Faculty of Medicine Titu Maiorescu University Bucharest Romania
Institute of Family Medicine and Public Health University of Tartu Tartu Estonia
The Romanian Association of International Medicine Manufacturers ARPIM Bucharest Romania
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24005626
- 003
- CZ-PrNML
- 005
- 20240412130936.0
- 007
- ta
- 008
- 240405e20240308sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fphar.2024.1369178 $2 doi
- 035 __
- $a (PubMed)38523639
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Jakubowski, Szczepan $u Department of Health Promotion and e-Health, Faculty of Health of Science, Jagiellonian University Medical College, Kraków, Poland
- 245 10
- $a Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries / $c S. Jakubowski, P. Kawalec, P. Holko, I. Kowalska-Bobko, M. Kamusheva, G. Petrova, P. Draganić, L. Fuksa, A. Männik, F. Ispán, V. Briedis, I. Bianchi, MS. Paveliu, T. Tesar
- 520 9_
- $a Objectives: The aim of this study was to characterize the reimbursement policy for orphan drugs (ODs) in Central and Eastern European (CEE) countries in relation to the availability and impact of clinical evidence, health technology assessment (HTA) procedure, selected economic indicators, and the drug type according to indications. Materials and methods: A list of authorized medicines with orphan designation and information about active substance, Anatomical Therapeutic Chemical (ATC) classification, and therapeutic area was extracted from the web-based register of the European Medicines Agency (EMA). A country-based questionnaire survey was performed between September 2021 and January 2022 in a group of selected experts from nine CEE countries (an invitation was sent to 11 countries). A descriptive and statistical analysis was conducted to determine statistical significance, correlations, between the drug or country characteristic and the positive recommendation or reimbursement of ODs.Results: The proportion of reimbursed orphan drugs differed between countries, ranging from 17.7% in Estonia to 49.6% in Hungary (p < 0.001). The odds that ODs were reimbursed were reduced in countries with a "strong" level of impact of drug safety and efficacy on reimbursement decisions (p=0.018), the presence of other additional specific clinical aspects (e.g., genomic data) considered in the reimbursement decision (p < 0.001) and mandatory (without exception) safety assessments (p=0.004). The probability that ODs were reimbursed was increased in countries with a "moderate" level of impact of drug safety and efficacy on reimbursement decisions (p=0.018), when reimbursement decisions are dependent on the EMA registration status and orphan drug designation (p < 0.001), the presence of the "positive HTA recommendation guarantees reimbursement" policy (p < 0.001), higher GDP per inhabitant (p=0.003), and higher healthcare expenditure (p < 0.001). Conclusion: We found that there are differences among CEE countries in the reimbursement of orphan drugs, and we identified aspects that may influence these differences. Safety, efficacy, and specific clinical aspect issues significantly influenced reimbursement decisions. Antineoplastic and immunomodulating agents drugs were the largest group of ODs and increased the chance of getting a positive recommendation. The higher GDP per inhabitant and healthcare expenditures per inhabitant were positively linked to the chance that an OD receives reimbursement.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kawalec, Pawel $u Department of Nutrition and Drug Research, Faculty of Health of Science, Jagiellonian University Medical College, Kraków, Poland
- 700 1_
- $a Holko, Przemyslaw $u Department of Nutrition and Drug Research, Faculty of Health of Science, Jagiellonian University Medical College, Kraków, Poland
- 700 1_
- $a Kowalska-Bobko, Iwona $u Health Policy and Management Department, Faculty of Health of Science, Jagiellonian University Medical College, Kraków, Poland
- 700 1_
- $a Kamusheva, Maria $u Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria
- 700 1_
- $a Petrova, Guenka $u Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria
- 700 1_
- $a Draganić, Pero $u Agency for Medicinal Products and Medical Devices of Croatia, Zagreb, Croatia $u Department of Biotechnology, University of Rijeka, Rijeka, Croatia
- 700 1_
- $a Fuksa, Leos $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Prague, Czechia
- 700 1_
- $a Männik, Agnes $u Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia
- 700 1_
- $a Ispán, Fanni $u Department of Reimbursement, National Institute of Health Insurance Fund Management, Budapest, Hungary
- 700 1_
- $a Briedis, Vitalis $u Department of Clinical Pharmacy of Lithuanian, University of Health Sciences, Kaunas, Lithuania
- 700 1_
- $a Bianchi, Ioana $u The Romanian Association of International Medicine Manufacturers. ARPIM, Bucharest, Romania
- 700 1_
- $a Paveliu, Marian Sorin $u Faculty of Medicine, Titu Maiorescu University, Bucharest, Romania
- 700 1_
- $a Tesar, Tomas $u Department of Organisation and Management in Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovakia
- 773 0_
- $w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 15 (20240308), s. 1369178
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38523639 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240405 $b ABA008
- 991 __
- $a 20240412130928 $b ABA008
- 999 __
- $a ok $b bmc $g 2075973 $s 1215388
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 15 $c - $d 1369178 $e 20240308 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
- LZP __
- $a Pubmed-20240405